A 12-year retrospective clinical study of patients who received peptide receptor radionuclide therapy (PRRT) for malignant neuroendocrine tumours demonstrates the long-term effectiveness of this treatment, which also allows patients to maintain a high quality of life.
The study is featured in the April issue of the Journal of Nuclear Medicine.
While PRRT has been used for more than 20 years to treat patients with inoperable or metastatic somatostatin receptor-positive tumours, knowledge of long-term outcomes has been limited.
A number of clinical studies have demonstrated PRRT's efficacy, and the overall response rate (including complete response, partial response, minor response, and stable disease) is about 70-80 percent for the two most commonly used radiopharmaceuticals: yttrium-90 (90Y)-DOTATOC (best suited for treating larger tumours) and lutetium-177 (177Lu)-DOTATATE (preferred for smaller tumours).
For patients who respond to PRRT, the prognosis is generally favourable, with a median time to disease progression of three to four years.
This study included 44 patients (27 men and 17 women) with advanced tumours and enhanced somatostatin receptor expression.
Mean age at initial diagnosis was 60 years (age range of 40 to 84).
Median follow-up was 80 months.
For 177Lu-PRRT, the mean number of cycles administered was 5.3 ± 2.5; for 90Y-PRRT, the mean number of cycles administered was 5.5 ± 2.6.
Median overall survival was 79 months, but 32 percent of the patients (14 of the 44 patients--6 men and 8 women) were still alive more than 12 years after starting PRRT.
Progressive disease occurring early after therapy began resulted in a poor prognosis, while women and patients with no more than two tumour sites seemed to benefit the most from PRRT.
"This study clearly demonstrates the long-term efficacy of PRRT over more than a decade in patients with metastatic tumour disease of neuroendocrine origin," explain Michael Gabriel, MD, and Irene J. Virgolini, MD, of the Department of Nuclear Medicine at the Medical University of Innsbruck in Austria.
They add that the research shows, "PRRT can be repeatedly used with limited side effects. From this perspective, a relatively stable tumour situation can be achieved over many years in a large number of patients.
None of the patients who were still alive at the end of the observation period were dialysis-dependent, and most of the patients showed a still very high KPI (key performance indicator), which underlines the positive effect of PRRT in terms of the quality of life."
Gabriel and Virgolini also point out the value of molecular imaging in therapeutic decision-making and, looking ahead, recommend "new prospective studies combining the nuclear medicine therapy approach with other therapeutic modalities to further increase efficiency."